Login
← Go Back
Bafna Pharmaceuticals
BAFNAPH · Pharma > Pharmaceuticals & Drugs · Chairman: Shanmugam Hemalatha Listing date: Nov. 13, 2012
Stock Price vs Company Growth
1d
2.5%
1w
2.7%
1m
8.8%
3m
11.0%
6m
12.6%
1y
18.9%
5y
38.0%
10y
9.5%
all
3.8%
Created with Highcharts 8.2.2SalesProfitPriceDividendQtr SalesOperating CashflowDec10Jun14Dec17Jun21Latest
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 73 2.5%
67.8
88.1
Company Overview
Sales
148 Cr
Growth: 1.2%
Profit after Tax
4.3 Cr
Growth: 958.4%
Micro Cap
173 Cr
P/E: 40.1x
Industry P/E: 31.2x
Created with Highcharts 8.2.2HistoricalGrowthValuationAttractivenessProfitabilityIndustryOutlookPriceStability10
Fundamentals
Sales (Cr) ₹ 148
Growth 1.2%
EBITDA 7.4%
P/S 1.2x
Dividend 0.0%
P/E 40.1x
Book Value ₹ 35.4
PEG Ratio 32.5x
ROE 5.3%
P/B 2.1x
Shareholding Pattern
Institutions
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep21Mar24
Promoters
Srjr Lifesciences Llp
90.0 %
Paras Bafna
0.21 %
Navin Bafna M
0.17 %
Amribai Bafna
0.01 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep21Mar24
Others
Monarch Networth Finserve Private Limited
1.4 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep21Mar24
Increase    Decrease    No change
Company Profile Detailed
Bafna Pharmaceuticals was incepted by Bafna Mahaveer Chand in 1981 as a proprietary concern. It was converted into a public limited company on 28th march 1995. The company started its own manufacturing unit in October 1984.Bafna Pharmaceuticals started its production with tablets facility and subsequently added capsule and oral syrup facilities respectively. BAFNA always focused on institutional and generic supply to keep its production line busy.
Investors (54)
mahaveer...
paras.ba...
monarch....